Format
Sort by
Items per page

Send to

Choose Destination

Links from NLM Catalog

Items: 1 to 20 of 603

1.

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S; MMRF CoMMpass Network, Russell SJ, Stewart AK.

Blood Cancer J. 2017 Sep 22;7(9):e612. doi: 10.1038/bcj.2017.94.

PMID:
28937974
2.

MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia.

Zhang T, Davidson-Moncada JK, Mukherjee P, Furman RR, Bhavsar E, Chen Z, Hakimpour P, Papavasiliou N, Tam W.

Blood Cancer J. 2017 Sep 8;7(9):e606. doi: 10.1038/bcj.2017.80. No abstract available.

PMID:
28885613
3.

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM.

Blood Cancer J. 2017 Sep 8;7(9):e603. doi: 10.1038/bcj.2017.85. Review.

PMID:
28885612
4.

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.

Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA.

Blood Cancer J. 2017 Sep 8;7(9):e605. doi: 10.1038/bcj.2017.81.

PMID:
28885611
5.

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O.

Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. No abstract available.

PMID:
28885610
6.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2017 Sep 1;7(9):e602. doi: 10.1038/bcj.2017.82. No abstract available.

PMID:
28862700
7.

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.

Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y.

Blood Cancer J. 2017 Sep 1;7(9):e601. doi: 10.1038/bcj.2017.84.

PMID:
28862699
8.

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Blood Cancer J. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83.

PMID:
28862698
9.

Impact of Notch disruption on myeloid development.

Francis OL, Chaudhry KK, Lamprecht T, Klco JM.

Blood Cancer J. 2017 Aug 25;7(8):e598. doi: 10.1038/bcj.2017.73. No abstract available.

10.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

11.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Aug 25;7(8):e596. doi: 10.1038/bcj.2017.71.

12.

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis.

Kostopoulos IV, Paterakis G, Pavlidis D, Kastritis E, Terpos E, Tsitsilonis OE, Papadhimitriou SI.

Blood Cancer J. 2017 Aug 25;7(8):e597. doi: 10.1038/bcj.2017.77. No abstract available.

13.

Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set.

Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS.

Blood Cancer J. 2017 Aug 25;7(8):e592. doi: 10.1038/bcj.2017.79. No abstract available.

14.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR.

Blood Cancer J. 2017 Aug 25;7(8):e595. doi: 10.1038/bcj.2017.70.

15.

Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish.

Lu JW, Hsieh MS, Hou HA, Chen CY, Tien HF, Lin LI.

Blood Cancer J. 2017 Aug 25;7(8):e593. doi: 10.1038/bcj.2017.74.

16.

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Cervera N, Carbuccia N, Mozziconacci MJ, Adélaïde J, Garnier S, Guille A, Murati A, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68. No abstract available.

17.

From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.

Jiménez C, Alonso-Álvarez S, Alcoceba M, Ordóñez GR, García-Álvarez M, Prieto-Conde MI, Chillón MC, Balanzategui A, Corral R, Marín LA, Gutiérrez NC, Puig N, Sarasquete ME, González M, García-Sanz R.

Blood Cancer J. 2017 Aug 25;7(8):e591. doi: 10.1038/bcj.2017.72.

18.

High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma.

Mills JR, Barnidge DR, Dispenzieri A, Murray DL.

Blood Cancer J. 2017 Aug 25;7(8):e590. doi: 10.1038/bcj.2017.75.

19.

Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.

Hou HA, Lu JW, Lin TY, Tsai CH, Chou WC, Lin CC, Kuo YY, Liu CY, Tseng MH, Chiang YC, Peng YL, Tang JL, Gong Z, Lin LI, Tien HF.

Blood Cancer J. 2017 Jul 28;7(7):e588. doi: 10.1038/bcj.2017.67.

20.

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C.

Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69. No abstract available.

Supplemental Content

Support Center